One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

Astra Zenecas lupusbehandling blir enklare att ta – ja till egenanvändning

Astra Zenecas läkemedel Saphnelo har fått en positiv rekommendation från CHMP för en ny beredningsform som gör det möjligt för patienter med SLE att själva ta l...

ZEISS O-INSPECT duo: The multifunctional measuring machine

ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.

Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”

Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

The key to successful collaboration between industry and academia

Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?

Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis

Free webinar organized by ZEISS.

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Mercodia AB

JMP Statistical Discovery

Double Bond avslutar licensavtal efter uteblivna betalningar

Läkemedelsbolaget Double Bond Pharmaceuticals avslutar ett förvärvsavtal med amerikanska Vivo Biopharma, som man anklagar för att inte ha uppfyllt sina åtaganden i form av milstolpsbetalningar....

Ukraine war fuels rise of totally resistent bacteria

War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.

Sobi inleder nytt samarbete inom sepsis

Särläkemedelsbolaget Sobi inleder ett nytt forskningssamarbete och en klinisk studie kring en potentiell behandling vid sepsis.

Cancer researcher: “We can do better and reduce suffering”

Lund University researcher Catharina Hagerling is developing innovative methods to understand metastatic cancer, aiming to create more targeted treatments for p...

Sahlgrenska Science Park

22 miljarder – så mycket kostar det att utveckla ett nytt läkemedel

Den genomsnittliga kostnaden för Big Pharma att ta ett läkemedel hela vägen från upptäckt till lansering var i fjol 2,23 miljarder dollar, motsvarande en bra bi...

Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...

What will be the next big hype after obesity? – An expert panel highlighted their top picks

What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...

Nytt läkemedel ska förenkla behandling av blödarsjuka

En ny typ av behandling mot hemofili, som bara behöver ges varannan månad, har godkänts av den amerikanska läkemedelsmyndigheten FDA.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).